SYRA
Syra Health Corp. Class A Common Stock
NASDAQ · Healthcare · Medical - Care Facilities · US
$0.93
+0.98%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 8.1M | 7.2M | 8.0M | 5.5M | 5.6M |
| Cost of Revenue | 4.9M | 4.7M | 6.3M | 4.1M | 4.6M |
| Gross Profit | 3.2M | 2.5M | 1.7M | 1.4M | 1.1M |
| Operating Expenses | |||||
| R&D Expense | 55.2K | 67.8K | 585.1K | 240.0K | — |
| SG&A Expense | 2.5M | 3.3M | 1.4M | 4.0M | 3.1M |
| General & Admin Expense | 1.7M | 3.3M | 4.8M | 4.0M | 3.1M |
| Selling & Marketing Expense | 567.4K | — | (3.3M) | — | — |
| Other Expenses | 539.6K | 20.5K | 3.4M | 52.1K | 45.6K |
| Total Operating Expenses | 3.1M | 3.4M | 5.4M | 4.3M | 3.2M |
| Cost and Expenses | 8.0M | 8.1M | 11.7M | 8.4M | 7.7M |
| Operating Income (EBIT) | 74.7K | (904.3K) | (3.8M) | (2.9M) | (2.1M) |
| Non-Operating | |||||
| Interest Income | 66.9K | 21.3K | 21.2K | 2.9K | 63.00 |
| Interest Expense | 10.9K | 13.3K | 15.6K | 53.7K | 28.5K |
| Net Interest Income | 56.0K | 8.0K | 5.6K | (50.7K) | (28.5K) |
| Other Non-Op Income/Expense | 56.0K | 8.0K | 5.6K | (50.7K) | (28.5K) |
| Non-Operating Income (excl Interest) | (64.1K) | (21.3K) | (21.2K) | (2.9K) | (63.00) |
| EBT (Pre-Tax Income) | 130.7K | (896.3K) | (3.8M) | (2.9M) | (2.1M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | 130.7K | (896.3K) | (3.8M) | (2.9M) | (2.1M) |
| Earnings from Cont. Ops | 130.7K | (896.3K) | (3.8M) | (2.9M) | (2.1M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 130.7K | (896.3K) | (3.8M) | (2.9M) | (2.1M) |
| Per Share | |||||
| Basic EPS | $0.01 | ($0.08) | ($0.52) | ($0.60) | ($0.36) |
| Diluted EPS | $0.01 | ($0.08) | ($0.52) | ($0.60) | ($0.29) |
| Revenue Per Share | $0.61 | $0.61 | $1.10 | $1.13 | $0.96 |
| Shares | |||||
| Basic Shares Outstanding | 13.2M | 11.9M | 7.3M | 4.9M | 5.9M |
| Diluted Shares Outstanding | 13.6M | 11.9M | 7.3M | 4.9M | 7.3M |
| Profitability Metrics | |||||
| EBITDA | 146.3K | (862.6K) | (3.7M) | (2.8M) | (2.1M) |
| D&A | 8.2K | 20.5K | 62.7K | 48.8K | 14.8K |
| EBIT | 138.8K | (883.1K) | (3.7M) | (2.9M) | (2.1M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026